444 related articles for article (PubMed ID: 28238958)
1. Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection.
Crespo J; Calleja JL; Fernández I; Sacristan B; Ruiz-Antorán B; Ampuero J; Hernández-Conde M; García-Samaniego J; Gea F; Buti M; Cabezas J; Lens S; Morillas RM; Salcines JR; Pascasio JM; Turnes J; Sáez-Royuela F; Arenas J; Rincón D; Prieto M; Jorquera F; Sanchez Ruano JJ; Navascués CA; Molina E; Moya AG; Moreno-Planas JM;
Clin Gastroenterol Hepatol; 2017 Jun; 15(6):945-949.e1. PubMed ID: 28238958
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
[TBL] [Abstract][Full Text] [Related]
3. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.
Yang Y; Wu FP; Wang WJ; Shi JJ; Li YP; Zhang X; Dang SS
World J Gastroenterol; 2019 Nov; 25(44):6551-6560. PubMed ID: 31802834
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.
Tao T; Jiang X; Chen Y; Song Y
Int J Infect Dis; 2017 Feb; 55():56-71. PubMed ID: 28040553
[TBL] [Abstract][Full Text] [Related]
5. Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience.
Naguib GG; Farid A; Hassan M; Elshafie A; Shazly YE; Shaker MK; Ezzat H; Safwat E; Ahmed OA; Dabbous H; Sherief AF; Hassany M; Elserafy M; Elsayed MH
Arab J Gastroenterol; 2021 Dec; 22(4):285-291. PubMed ID: 34531135
[TBL] [Abstract][Full Text] [Related]
6. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus.
Rupp C; Hippchen T; Neuberger M; Sauer P; Pfeiffenberger J; Stremmel W; Gotthardt DN; Mehrabi A; Weiss KH
World J Gastroenterol; 2018 Mar; 24(12):1353-1360. PubMed ID: 29599610
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Chronic HCV Infection with the New Direct Acting Antivirals (DAA): First Report of a Real World Experience in Southern Brazil.
Cheinquer H; Sette H; Wolff FH; de Araujo A; Coelho-Borges S; Soares SRP; Barros MFA
Ann Hepatol; 2017; 16(5):727-733. PubMed ID: 28809742
[TBL] [Abstract][Full Text] [Related]
8. Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience.
Muñoz-Gómez R; Rincón D; Ahumada A; Hernández E; Devesa MJ; Izquierdo S; Ortiz M; Hernández-Albujar A; Fernández-Rodríguez C; Calvo M; González R; Lozano M; Castellano G; Fernández-Vázquez I
J Viral Hepat; 2017 Jun; 24(6):464-471. PubMed ID: 27976490
[TBL] [Abstract][Full Text] [Related]
9. Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis.
Sanai FM; Altraif IH; Alswat K; AlZanbagi A; Babatin MA; AlMousa A; Almutairi NH; Aljawad MS; Alghamdi AS; Aljumah AA; Alalwan AM; Al-Hamoudi WK; Assiri AM; Dahlan Y; Alsahafi A; Alothmani HS; AlSaleemi MS; Mousa WA; Albenmousa A; Awny A; Albiladi H; Abdo AA; AlGhamdi H
J Infect; 2018 Jun; 76(6):536-542. PubMed ID: 29742470
[TBL] [Abstract][Full Text] [Related]
10. High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar.
Hlaing NKT; Nangia G; Tun KT; Lin S; Maung MZ; Myint KT; Kyaw AMM; Maung ST; Sein Win S; Bwa AH; Loza BL; Win KM; Reddy KR
J Viral Hepat; 2019 Oct; 26(10):1186-1199. PubMed ID: 31104344
[TBL] [Abstract][Full Text] [Related]
11. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis.
Reddy KR; Bourlière M; Sulkowski M; Omata M; Zeuzem S; Feld JJ; Lawitz E; Marcellin P; Welzel TM; Hyland R; Ding X; Yang J; Knox S; Pang P; Dvory-Sobol H; Subramanian GM; Symonds W; McHutchison JG; Mangia A; Gane E; Mizokami M; Pol S; Afdhal N
Hepatology; 2015 Jul; 62(1):79-86. PubMed ID: 25846144
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.
Alonso S; Riveiro-Barciela M; Fernandez I; Rincón D; Real Y; Llerena S; Gea F; Olveira A; Fernandez-Carrillo C; Polo B; Carrión JA; Gómez A; Devesa MJ; Baliellas C; Castro Á; Ampuero J; Granados R; Pascasio JM; Rubín A; Salmeron J; Badia E; Planas JM; Lens S; Turnes J; Montero JL; Buti M; Esteban R; Fernández-Rodríguez CM
J Viral Hepat; 2017 Apr; 24(4):304-311. PubMed ID: 27935168
[TBL] [Abstract][Full Text] [Related]
13. Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients.
Abdel-Moneim A; Aboud A; Abdel-Gabbar M; Zanaty M; Ramadan M
Dig Dis Sci; 2018 May; 63(5):1341-1347. PubMed ID: 29546644
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.
Welzel TM; Nelson DR; Morelli G; Di Bisceglie A; Reddy RK; Kuo A; Lim JK; Darling J; Pockros P; Galati JS; Frazier LM; Alqahtani S; Sulkowski MS; Vainorius M; Akushevich L; Fried MW; Zeuzem S;
Gut; 2017 Oct; 66(10):1844-1852. PubMed ID: 27418632
[TBL] [Abstract][Full Text] [Related]
15. Sofosbuvir-ledipasvir with or without ribavirin for chronic hepatitis C genotype-1 and 6: real-world experience in Vietnam.
Thu Thuy PT; Bunchorntavakul C; Tan Dat H; Palecki J; Reddy KR
Antivir Ther; 2018; 23(5):415-423. PubMed ID: 29303482
[TBL] [Abstract][Full Text] [Related]
16. Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.
Tapper EB; Bacon BR; Curry MP; Dieterich DT; Flamm SL; Guest LE; Kowdley KV; Lee Y; Tsai NC; Younossi ZM; Afdhal NH
J Viral Hepat; 2017 Jan; 24(1):22-27. PubMed ID: 27730717
[TBL] [Abstract][Full Text] [Related]
17. Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection.
Liu CH; Su TH; Liu CJ; Hong CM; Yang HC; Tseng TC; Chen PJ; Chen DS; Kao JH
J Gastroenterol Hepatol; 2019 Sep; 34(9):1620-1625. PubMed ID: 30693965
[TBL] [Abstract][Full Text] [Related]
18. Direct-acting antiviral agents in patients with hepatitis C genotype 1-4 infections in a tertiary hospital.
Del Rio-Valencia JC; Asensi-Diez R; Villalobos-Torres L; Muñoz Castillo I
Rev Esp Quimioter; 2018 Jun; 31(3):226-236. PubMed ID: 29771105
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection.
Perelló C; Carrión JA; Ruiz-Antorán B; Crespo J; Turnes J; Llaneras J; Lens S; Delgado M; García-Samaniego J; García-Paredes F; Fernández I; Morillas RM; Rincón D; Porres JC; Prieto M; Lázaro Ríos M; Fernández-Rodríguez C; Hermo JA; Rodríguez M; Herrero JI; Ruiz P; Fernández JR; Macías M; Pascasio JM; Moreno JM; Serra MÁ; Arenas J; Real Y; Jorquera F; Calleja JL;
J Viral Hepat; 2017 Mar; 24(3):226-237. PubMed ID: 27976491
[TBL] [Abstract][Full Text] [Related]
20. Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.
Butt AA; Yan P; Shaikh OS; Chung RT; Sherman KE;
Liver Int; 2016 Sep; 36(9):1275-83. PubMed ID: 26928927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
